SYNTHETIC CHEMISTRY SUPPORT FOR THE TDB MEDICINAL CHEMISTRY TEAM

治疗发展处(TDB)在人类治疗学开发方面进行转化研究，旨在推动小分子和生物药物候选药物在药物开发管道中向前发展。TDB的一个关键重点领域是有效地确定罕见和被忽视疾病的临床前开发候选对象。为了完成这一使命，TDB组建了由化学家、药理学家、吸收、分配、代谢和排泄(ADME)/药代动力学(PK)专家以及毒理学家组成的团队，紧密合作，对有前景的治疗先导化合物进行药物化学优化。TDB药物化学家聘请合同研究组织(CRO)并行支持多个铅生成和铅优化项目。目前，TDB药物化学团队正在开展以下项目：1)开发疟疾传播阻断药物，2)开发罕见ADCK3扩增癌症的候选治疗药物。

The Therapeutic Development Branch (TDB) conducts translational research in human therapeutics development and aims to move small molecule and biologic drug candidates forward in the drug development pipeline. A critical focus area for TDB is to efficiently identify preclinical development candidates for rare and neglected diseases. To accomplish this mission, TDB builds teams of chemists; pharmacologists; absorption, distribution, metabolism, and excretion (ADME)/pharmacokinetics (PK) experts; and toxicologists to work closely together to perform medicinal chemistry optimization on promising therapeutic lead compounds. TDB medicinal chemists engage contract research organizations (CROs) to support multiple lead generation and lead optimization projects in parallel. Currently, the TDB medicinal chemistry team is working on the following projects: 1) Development of malaria transmission-blocking drugs, and 2) Development of therapeutic candidates for rare ADCK3-amplified cancers.